
MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 3 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 13-16730-01	Docket or Reference No.: 030-11551	
	Amendment No. 22		

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at 801 N State St., Greenfield, Indiana, 46140.
- 11. The Radiation Safety Officer (RSO) for this license is Justin P. Chang, M.D.
- 12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)	Material and Use
James Blahunka, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
James R. Bognanno, M.D.	10 CFR 35.100,10 CFR 35.200
Justin P. Chang, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)
Julia J. Compton, M.D.	10 CFR 35.300 (limited to the parenteral administration of radium Ra-223 dichloride)
Thomas C. Dugan, M.D.	10 CFR 35.300
Stanley S. Givens, M.D.	10 CFR 35.300
Tarun R. Jindal, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
Kenyon K. Kopecky, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
David Kurlander, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Christopher A. Leagre, M.D.	10 CFR 35.300
Robert Liebross, M.D.	10 CFR 35.300

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	SSION PAGE 3 OF 3	PAGES
MATERIALS LICENSE	License No.: 13-16730-01	Docket or Reference No.: 030-11551	
SUPPLEMENTARY SHEET	Amendment No. 22		
representations, and procedures containe those procedures that are required to be licensee's ability to make changes to the	10 CFR 35.100,10 CFR 35.200; 10 Ciodide I-131) in this license, the licensee shall conducted in the documents, including any enclosubmitted in accordance with the regular radiation protection program as provided less the statements, representations, are the regulations.	eral administration of radium Ra-223 dichloride) CFR 35.300 (limited to the oral administration of solution of solution applies to the statements, usures, listed below. This license condition applies tions. Additionally, this license condition does not a for in 10 CFR 35.26. The U.S. Nuclear Regulator and procedures in the licensee's application and	only to limit the
	FOR	THE U.S. NUCLEAR REGULATORY COMMISSION	NC
Date: August 17, 2020		aura B. Cender	
	r	Region 3	